Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy

    ... patients with low- or intermediate 1-risk (lower risk) myelodysplastic syndromes (MDS) and thrombocytopenia , but its long-term toxicity ...

    Research Article last updated 07/11/2017 - 10:22am.

  2. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

    ... (LEN) is the standard of care for the lower-risk myelodysplastic syndromes (MDS) patients with deletion 5q, 35% will not respond to or do ...

    Research Article last updated 07/11/2017 - 10:11am.

  3. Making Progress for Myelodysplastic Syndromes

    ... Article Link:  Making Progress for Myelodysplastic Syndrome Article Source:  ... Myelodysplastic syndromes (MDS) are rare, which can make them difficult to study. The ...

    Article last updated 07/26/2017 - 10:25am.

  4. Haploidentical transplant in patients with myelodysplastic syndrome

    ... treatment in patients with intermediate or high-risk myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell ... Bone Marrow Diseases:  myelodysplastic syndromes (MDS) ...

    Research Article last updated 10/04/2017 - 9:19am.

  5. Origins of myelodysplastic syndromes after aplastic anemia

    ...

    Research Article last updated 09/18/2017 - 9:34am.

  6. New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes

    ... June 1, 2017 In myelodysplastic syndromes (MDS), somatic mutations occur in five major categories: RNA ...

    Research Article last updated 06/26/2017 - 9:16am.

  7. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents

    ... The prognosis of patients with myelodysplastic syndromes (MDS) following failure of hypomethylating agent (HMA) therapy is ...

    Research Article last updated 06/26/2017 - 9:13am.

  8. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes

    ... March 12, 2015 Myelodysplastic syndromes are a group of heterogeneous clonal hematologic malignancies that ...

    Research Article last updated 06/21/2017 - 11:10am.

  9. Therapy-related myelodysplastic syndromes-specific risk stratification: Are we putting the cart before the horse?

    ... Bone Marrow Diseases:  myelodysplastic syndromes (MDS) ...

    Research Article last updated 09/11/2017 - 9:05am.

  10. Promising trial results for lower-risk MDS drug

    ... for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open- Article ...

    Article last updated 09/07/2017 - 11:08am.